A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study.
Van Calster, Ben ; Valentin, Lil LU
; Van Holsbeke, Caroline
; Zhang, Jingjing
; Jurkovic, Davor
; Lissoni, Andrea Alberto
; Testa, Antonia Carla
; Czekierdowski, Artur
; Fischerová, Daniela
and Domali, Ekaterini
, et al.
(2011)
In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
20.
p.2420-2428
- Abstract
- BACKGROUND: The CA-125 tumor marker has limitations when used to distinguish between benign and malignant ovarian masses. We therefore establish likelihood curves of six subgroups of ovarian pathology based on CA-125 and menopausal status.METHODS: This cross-sectional study conducted by the International Ovarian Tumor Analysis group involved 3,511 patients presenting with a persistent adnexal mass that underwent surgical intervention. CA-125 distributions for six tumor subgroups (endometriomas and abscesses, other benign tumors, borderline tumors, stage I invasive cancers, stage II-IV invasive cancers, and metastatic tumors) were estimated using kernel density estimation with stratification for menopausal status. Likelihood curves for the... (More)
- BACKGROUND: The CA-125 tumor marker has limitations when used to distinguish between benign and malignant ovarian masses. We therefore establish likelihood curves of six subgroups of ovarian pathology based on CA-125 and menopausal status.METHODS: This cross-sectional study conducted by the International Ovarian Tumor Analysis group involved 3,511 patients presenting with a persistent adnexal mass that underwent surgical intervention. CA-125 distributions for six tumor subgroups (endometriomas and abscesses, other benign tumors, borderline tumors, stage I invasive cancers, stage II-IV invasive cancers, and metastatic tumors) were estimated using kernel density estimation with stratification for menopausal status. Likelihood curves for the tumor subgroups were derived from the distributions.RESULTS: Endometriomas and abscesses were the only benign pathologies with median CA-125 levels above 20 U/mL (43 and 45, respectively). Borderline and invasive stage I tumors had relatively low median CA-125 levels (29 and 81 U/mL, respectively). The CA-125 distributions of stage II-IV invasive cancers and benign tumors other than endometriomas or abscesses were well separated; the distributions of the other subgroups overlapped substantially. This held for premenopausal and postmenopausal patients. Likelihood curves and reference tables comprehensibly show how subgroup likelihoods change with CA-125 and menopausal status.Conclusions and Impact: Our results confirm the limited clinical value of CA-125 for preoperative discrimination between benign and malignant ovarian pathology. We have shown that CA-125 may be used in a different way. By using likelihood reference tables, we believe clinicians will be better able to interpret preoperative serum CA-125 results in patients with adnexal masses. Cancer Epidemiol Biomarkers Prev; ©2011 AACR. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2168498
- author
- Van Calster, Ben
; Valentin, Lil
LU
; Van Holsbeke, Caroline
; Zhang, Jingjing
; Jurkovic, Davor
; Lissoni, Andrea Alberto
; Testa, Antonia Carla
; Czekierdowski, Artur
; Fischerová, Daniela
and Domali, Ekaterini
, et al. (More)
- Van Calster, Ben
; Valentin, Lil
LU
; Van Holsbeke, Caroline
; Zhang, Jingjing
; Jurkovic, Davor
; Lissoni, Andrea Alberto
; Testa, Antonia Carla
; Czekierdowski, Artur
; Fischerová, Daniela
; Domali, Ekaterini
; Van de Putte, Gregg
; Vergote, Ignace
; Van Huffel, Sabine
; Bourne, Tom
and Timmerman, Dirk
(Less)
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
- volume
- 20
- pages
- 2420 - 2428
- publisher
- American Association for Cancer Research
- external identifiers
-
- wos:000296765200011
- pmid:21908724
- scopus:81155154340
- pmid:21908724
- ISSN
- 1538-7755
- DOI
- 10.1158/1055-9965.EPI-11-0422
- language
- English
- LU publication?
- yes
- id
- e07a57d4-eb18-4452-8f18-2522d60c5e8b (old id 2168498)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21908724?dopt=Abstract
- date added to LUP
- 2016-04-04 09:28:32
- date last changed
- 2022-01-29 18:00:15
@article{e07a57d4-eb18-4452-8f18-2522d60c5e8b,
abstract = {{BACKGROUND: The CA-125 tumor marker has limitations when used to distinguish between benign and malignant ovarian masses. We therefore establish likelihood curves of six subgroups of ovarian pathology based on CA-125 and menopausal status.METHODS: This cross-sectional study conducted by the International Ovarian Tumor Analysis group involved 3,511 patients presenting with a persistent adnexal mass that underwent surgical intervention. CA-125 distributions for six tumor subgroups (endometriomas and abscesses, other benign tumors, borderline tumors, stage I invasive cancers, stage II-IV invasive cancers, and metastatic tumors) were estimated using kernel density estimation with stratification for menopausal status. Likelihood curves for the tumor subgroups were derived from the distributions.RESULTS: Endometriomas and abscesses were the only benign pathologies with median CA-125 levels above 20 U/mL (43 and 45, respectively). Borderline and invasive stage I tumors had relatively low median CA-125 levels (29 and 81 U/mL, respectively). The CA-125 distributions of stage II-IV invasive cancers and benign tumors other than endometriomas or abscesses were well separated; the distributions of the other subgroups overlapped substantially. This held for premenopausal and postmenopausal patients. Likelihood curves and reference tables comprehensibly show how subgroup likelihoods change with CA-125 and menopausal status.Conclusions and Impact: Our results confirm the limited clinical value of CA-125 for preoperative discrimination between benign and malignant ovarian pathology. We have shown that CA-125 may be used in a different way. By using likelihood reference tables, we believe clinicians will be better able to interpret preoperative serum CA-125 results in patients with adnexal masses. Cancer Epidemiol Biomarkers Prev; ©2011 AACR.}},
author = {{Van Calster, Ben and Valentin, Lil and Van Holsbeke, Caroline and Zhang, Jingjing and Jurkovic, Davor and Lissoni, Andrea Alberto and Testa, Antonia Carla and Czekierdowski, Artur and Fischerová, Daniela and Domali, Ekaterini and Van de Putte, Gregg and Vergote, Ignace and Van Huffel, Sabine and Bourne, Tom and Timmerman, Dirk}},
issn = {{1538-7755}},
language = {{eng}},
pages = {{2420--2428}},
publisher = {{American Association for Cancer Research}},
series = {{Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}},
title = {{A Novel Approach to Predict the Likelihood of Specific Ovarian Tumor Pathology Based on Serum CA-125: A Multicenter Observational Study.}},
url = {{http://dx.doi.org/10.1158/1055-9965.EPI-11-0422}},
doi = {{10.1158/1055-9965.EPI-11-0422}},
volume = {{20}},
year = {{2011}},
}